HCRP1 regulates proliferation, invasion, and drug resistance via EGFR signaling in prostate cancer

Abstract Previous studies showed that HCRP1 is decreased in tumor cells compared with normal tissue, and functions as a tumor suppressor. However, its expression pattern and function in human prostate cancer remain unclear. In this study we examined HCRP1 expression in prostate cancer cell lines via...

Full description

Saved in:
Bibliographic Details
Published in:Biomedicine & pharmacotherapy 2017-07, Vol.91, p.202-207
Main Authors: Sun, Liang, Lü, Jiaju, Ding, Sentai, Bi, Dongbin, Ding, Kejia, Niu, Zhihong, Liu, Ping
Format: Article
Language:English
Subjects:
Cell Line, Tumor
Cell Proliferation
Drug resistance
Drug Resistance, Multiple
Drug Resistance, Neoplasm
EGFR
Endosomal Sorting Complexes Required for Transport - metabolism
HCRP1 prostate cancer
Humans
Internal Medicine
Invasion
Male
Medical Education
Models, Biological
Neoplasm Invasiveness
Proliferation
Prostatic Neoplasms - metabolism
Prostatic Neoplasms - pathology
Receptor, Epidermal Growth Factor - metabolism
Signal Transduction
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Previous studies showed that HCRP1 is decreased in tumor cells compared with normal tissue, and functions as a tumor suppressor. However, its expression pattern and function in human prostate cancer remain unclear. In this study we examined HCRP1 expression in prostate cancer cell lines via western blotting. Thereafter, we performed CCK-8 assay and matrigel invasion assay after cells were transfected with HCRP1 overexpression plasmid or siRNA. We further investigated the possible mechanism involved in HCRP1’s regulation to prostate cancer cell proliferation and invasion. We found that HCRP1 negatively regulates EGFR activity and expression of its downstream proteins. Moreover, we found that HCRP1 is negatively correlated with multi-drug resistant related proteins after cells were treated with paclitaxel, cisplatin or gefitinib, indicating its inhibiting effect of chemotherapy resistance. In summary, our results provided evidence that HCRP1 is a negative regulator in prostate cancer progression, metastasis and multi-drug resistance.
ISSN:0753-3322
1950-6007
DOI:10.1016/j.biopha.2017.04.040